Overview
A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)
Status:
Completed
Completed
Trial end date:
2006-05-14
2006-05-14
Target enrollment:
0
0
Participant gender:
All
All
Summary
A study of different doses of MK-0431 in participants with type 2 diabetes mellitus. There have been 3 extensions to the base study (Extension 1: up to Week 52, Extension 2: up to Week 106, and Extension 3: up to Week 158). The primary hypothesis for the study is that In participants with type 2 diabetes who have inadequate glycemic control, after 12 weeks of treatment, a dose-response will be seen across once-daily doses of MK-0431 in lowering hemoglobin A1C (HbA1c).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.Treatments:
Metformin
Sitagliptin Phosphate
Criteria
Inclusion Criteria:- Men and non-pregnant women
- Fasting plasma glucose >= 130 mg/dL
- HbA1c >=6.5% and >10.0%
Exclusion Criteria:
- You have a history of type I diabetes
- You are on a weight loss program with ongoing weight loss or taking weight loss
medication
- You have had surgery within 30 days
- You hvae hepatitis B or C.